Results 71 to 80 of about 137,002 (346)
Nephroprotective potential of glucagon-like peptide-1 receptor agonists
Сахарный диабет, 2020 Patients with diabetes mellitus (DM), which is a key factor in the development of kidney diseases, are increasingly competing for limited healthcare resources.
Minara S. Shamkhalova +2 more
doaj +1 more source
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Therapeutic Advances in Endocrinology and MetabolismGlucagon-like peptide 1 receptor agonists (GLP-1RAs) have emerged as promising therapeutic agents with potent anti-inflammatory properties and diverse clinical implications.
S. Alharbi
semanticscholar +1 more source
Comment. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? [PDF]
, 2014 Adam M.
A. M. Deane +6 more
core +1 more source
Glucagon-Like Peptide-1 Receptor Imaging for Localization of Insulinomas [PDF]
The Journal of Clinical Endocrinology & Metabolism, 2009 The surgical removal of insulinomas is hampered by difficulties to localize it using conventional radiological procedures. Recently these tumors were shown to exhibit a very high density of glucagon-like peptide-1 receptors (GLP-1R) in vitro that may be used as specific targets for in vivo receptor radiolabeling.The objective of the study was to test ...
Christ, Emanuel +9 more
openaire +4 more sources
Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma
Molecular Oncology, EarlyView.PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga +2 more
wiley +1 more source
Hepatology, EarlyView., 2022 NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger +7 more
wiley +1 more source
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis [PDF]
Journal of Biological Chemistry, 2003 Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and augments beta cell mass via activation of beta cell proliferation and islet neogenesis. We examined whether GLP-1 receptor signaling modifies the cellular susceptibility to apoptosis. Mice administered streptozotocin (STZ), an agent known to induce beta cell apoptosis, exhibit sustained ...
Li, Yazhou +5 more
openaire +3 more sources
Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment
Molecular Oncology, EarlyView.This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley +1 more source
The glucagon-like Peptide-2 [PDF]
, 2011 Multiple peptide hormones produced within the gastrointestinal system act also in the central nervous system and aid in the regulation of energy homeostasis and metabolism. The list of these peptides is progressively increasing and includes glucagon-like
Mule, Flava
core
Allosteric optical control of a class B G-protein-coupled receptor [PDF]
, 2016 Allosteric regulation promises to open up new therapeutic avenues by increasing drug specificity at G‐protein‐coupled receptors (GPCRs). However, drug discovery efforts are at present hampered by an inability to precisely control the allosteric site ...
Broichhagen +20 more
core +1 more source